MISSOURI CANCER ASSOCIATES, LLC
Medical and Radiation Oncology ■ Hematology

MEDICAL ONCOLOGY & HEMATOLOGY
Joseph J. Muscato, M.D.
Mary S. Muscato, M.D.
David M. Schlossman, M.D., Ph.D.
Pamela J. Honeycutt, M.D., Ph.D.
Mark J. Vellek. M.D.
Michael C. Trendle, M.D.
Elangovan Balakrishnan, M.D.
Umasankar Ramadoss, M.D.
Mark M. Tungesvik, M.D.
Syndee Serr, ANP

RADIATION ONCOLOGY
Steven J. Westgate, M.D.
Mark P. Bryer, M.D.
Joseph Bean, M.D.
Jay Allen, M.D.
William E. Decker, M.D.

RADIATION THERAPY
(573) 442-5525
(573) 442-2124 Fax

PHARMACY
(573) 817-8527

BUSINESS OFFICE
(573) 875-7082

RESEARCH
(573) 817-8538

September 1, 2009

Materials Licensing Branch
Attn: Toye Simmons
US NRC Region III
2443 Warrensville Road, Suite 210
Lisle, IL 60532-4352
(F) 630-829-9782

RE: License #24-32604-01
Docket #030-37082

To Whom It May Concern:

Please add Laura Sievert, MD, and David Brummett, MD, as Authorized Users under 35.200 and remove Steven Crooks, PhD (AMP) from the license listed above for Missouri Cancer Associates, LLC.

Attached is a copy of the license as they are currently listed.

Please do not hesitate to contact me if you have any questions or concerns.

Sincerely,

Willis Brumley, MS
Radiation Safety Officer

1705 E. BROADWAY, STE. 100, COLUMBIA, MISSOURI 65201 ■ (573) 874-7800 ■ Toll Free: 1-866-724-2413 ■ Fax (573) 443-3627
603 WEST PIERCE, KIRKSVILLE, MISSOURI 63501 ■ (660) 785-1050 ■ FAX: (660) 785-1055
www.missouricancer.com

A MEMBER OF US ONCOLOGY RESEARCH

RECEIVED SEP 0 9 2009

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 77

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated **December 12, 2008**,
1. Boone Hospital Center	3. License number 24-01565-01 is amended in its entirety to read as follows:
2. 1600 East Broadway Columbia, MO 65201	4. Expiration date April 30, 2015
	5. Docket No. 030-02304 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	D. **Sealed sources (Oncura (Medi-Physics) Model No. 6711, Theragenics Model No. 200, Bard Model STM-1251, 3M Model No. 6500 Series, Tracer-Lab, Model No.RA-1)**	D. **Not to exceed 270 millicuries for cesium-137 and 25 millicuries for strontium-90 and 4560 millicuries total**
E. Cesium-137 permitted by 10 CFR 35.400	E. Sealed sources (Nuclear Associates, Model Nos. 67-800 and 67-601)	E. **240 millicuries for Model No. 67-800 and 130 millicuries for Model No. 67-601)**
F. Cesium-137	F. Sealed source (Tech. Ops. Model No. 77032)	F. **95 millicuries**
G. Any byproduct material permitted by 10 CFR 31.11	H. Prepackaged kit	H. 50 millicuries
H. Depleted uranium	I. Metal	I. 999 kilograms

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-01565-01

Docket or Reference Number
030-02304

Amendment No. 77

9. Authorized use:

   A. Any uptake, dilution and excretion study permitted by 10CFR 35.100.

   B. Any imaging and localization study permitted by 10CFR 35.200.

   C. Any diagnostic study or therapy procedure permitted by 10CFR 35.300.

   D. Any manual brachytherapy procedure permitted by 10CFR 35.400.

   E. and F. For storage only incident to disposal.

   G. In vitro studies.

   H. For use as shielding material.

CONDITIONS

10. Licensed material may be used at the licensee's facilities located at Boone Hospital Center, 1600 East Broadway, Columbia, Missouri.

11. Radiation Safety Officer for this license is Liesje Myers, CNMT.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user in accordance with 10CFR 35.13 and 35.14.

    B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
John Baird, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures permitted by 35.300 and 31.11.
Vijay Sadhu, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures permitted by and 31.11.
Barbara Tellerman, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures permitted by and 31.11.
Charles M. Swaney, M.D.	10 CFR 35.100, 35.200, 31.11, and iodine-131 for diagnostic procedures and the treatment of hyperthyroidism permitted by 35.300.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-01565-01

Docket or Reference Number
030-02304

Amendment No. 77

Mark Bryer, M.D.	10 CFR 35.300 and 35.400.
Steven Westgate, M.D.	10 CFR 35.300 and 35.400.
Joseph M. Bean, M.D.	10 CFR 35.300 and 35.400.
Terry J. Elwing, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures permitted by 35.300 and 31.11.
Laura J. Sievert, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures and for treatment of hyperthyroidism permitted by 35.300 and 31.11.
James Allen, M.D.	10 CFR 35.300 and 35.400.
Maxwell Lazinger, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures permitted by 35.300 and 31.11.
David Perry Brummett, M.D.	10 CFR 35.100, 35.200, iodine-131 for diagnostic procedures and the treatment of hyperthyroidism permitted by 35.300 and 31.11.
William E. Decker, M.D.	10 CFR 35.300 and 35.400.
Hun Tai Lee, M.D.	10 CFR 35.100, 35.200, iodine-131 diagnostic procedures permitted by 35.300 and 31.11.

14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

C. Sealed sources need not be tested if they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material.

D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested befoe use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for

leakage and/or contamination.

E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

G. Records of leak test results shall be kept in units of microcuries and shall be maintained for 3 years.

15. The licensee shall conduct a physical inventory every 3 months to account for all sources and/or devices received and possessed pursuant to 10 CFR 35.59, 10 CFR 35.400 and every 6 months for all other sources and/or devices. Records of inventories shall be maintained for 5 years from the date of each inventory, and shall include the information required in 10CFR 35.59(g).

16. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

17. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10CFR 30.35(d) for establishing decommissioning financial assurance.

18. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-01565-01

Docket or Reference Number
030-02304

Amendment No. 77

19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated March 8, 2005;

    B. Letters dated September 10, 1990, October 18, 2006, November 14, 2006, January 15, 2007, August 1, 2007, October 3, 2007, **December 12, 2008**;

    C. Facsimile dated April 20, 2005, transmitting letter dated October 29, 2004; and

    D. Facsimile letter dated April 2, 2007, October 29, 2007 and November 6, 2007.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JAN 13 2009

By James Mullauer
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III

Missouri Cancer Associates
1705 E Broadway, Plaza 4
Suite 100, Radiation Therapy
Columbia, MO 65201

CERTIFIED MAIL™

7006 2760 0002 4323 7753

UNITED STATES POSTAGE
PITNEY BOWES
02 1M
0004216769
$ 05.71⁰
SEP 04 2009
MAILED FROM ZIP CODE 65201

US NRC Region III
Materials Licensing Branch
2443 Warrensville Road, Suite 210
Lisle, Illinois 60532-4352

ATTN: Toye Simmons